Overview

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Status:
Recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
This is a phase I/II Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid leukemia
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Therapeutic Advances in Childhood Leukemia Consortium
Collaborator:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal
Azacitidine
Nivolumab